



KAMUYU AYDINLATMA PLATFORMU

GEN İLAÇ VE SAĞLIK ÜRÜNLERİ SANAYİ VE TİCARET A.Ş. Material Event Disclosure (General)

Summary

Recent Development Regarding One of Our R&D Project

Material Event Disclosure General

Related Companies []

Related Funds []

Material Event Disclosure General	
Update Notification Flag	Hayır (No)
Correction Notification Flag	Hayır (No)
Date Of The Previous Notification About The Same Subject	-
Postponed Notification Flag	Hayır (No)
Announcement Content	
Explanations	

Our company Gen İlaç ve Sağlık Ürünleri San. ve Tic. A.Ş. (GEN) is pleased to publicly share our efforts to develop an innovative research drug in line with its growth, globalization and innovation strategies:

The first patient was included in the multicenter, randomized, double-blind, placebo-controlled, parallel-group Phase 2 trial in which the clinical efficacy and safety of GN-037 topical cream is evaluated in the treatment of mild to moderate plaque psoriasis. Formulation of GN-037 topical cream which is our company's investigational drug in the clinical development phase was developed by GEN R&D laboratories.

A total of 190 patients aged 18-65 years who were diagnosed with plaque psoriasis at 12 research centers are planned to be included in this Phase 2 study. Patients included in the study will receive GN-037 cream or clobetasol 17-propionate or placebo treatments twice a day, morning and evening, for four weeks. At the end of the four-week treatment period, the patients will be followed up for an additional four weeks. The total duration of the phase 2 study is anticipated to be approximately 12 months. Details of this clinical trial is accessible at clinicaltrials.gov database (<https://www.clinicaltrials.gov>) with the trial identifier code NCT05706870.

Psoriasis is a recurrent, chronic skin disease that can occur in various clinical forms. The frequency of psoriasis varies in different societies and geographic regions. Different published studies report that the frequency of psoriasis is 1,5-2% in the general population. 70-80% of psoriasis patients have limited/localized disease and are managed with topical therapy only. In this respect, topical treatment is the most common form of treatment in psoriasis management. Based on the current information it is anticipated that there are approximately 1.300.000 psoriasis patients in Turkey and of these patients 900.000 are treated with topical drugs.

It is announced to the public with respect.

We proclaim that our above disclosure is in conformity with the principles set down in “Material Events Communiqué” of Capital Markets Board, and it fully reflects all information coming to our knowledge on the subject matter thereof, and it is in conformity with our books, records and documents, and all reasonable efforts have been shown by our Company in order to obtain all information fully and accurately about the subject matter thereof, and we’re personally liable for the disclosures.